Group 1 - Biogen is undergoing a transformation with a "Fit for Growth" program aimed at improving its organizational structure and overall efficiency [2] - The company has seen significant changes in leadership, with Robin Kramer recently transitioning to the CFO role, indicating a strategic shift within the financial team [2][4] - The revised strategy implemented by the new leadership has been positively received, suggesting a promising outlook for Biogen's future [4] Group 2 - The conference highlights the importance of understanding Biogen's current foundation and future outlook as it navigates through organizational changes [2] - The discussion emphasizes the need for clarity on the various levers that the company can utilize to enhance its performance moving forward [2]

Financial Data and Key Metrics Changes - The company is executing a Fit for Growth program aimed at optimizing its cost structure, with a target of achieving $800 million in net cost savings by the end of the year [44] - The company has successfully executed activities necessary to yield $1 billion in growth and $800 million in net savings [44] Business Line Data and Key Metrics Changes - The company has shifted its focus from primarily neuroscience to include immunology and nephrology, with significant investments in four ongoing product launches [4][9] - The company has nine programs in phase three or phase three ready, indicating a robust pipeline for future growth [7] Market Data and Key Metrics Changes - The U.S. launch of Skyclaris is in a steady growth phase, while initial launches in Europe are progressing similarly [48] - The company has received approval in Brazil for Skyclaris, which is expected to be an important market [49] Company Strategy and Development Direction - The company is focused on redeploying capital from its MS business to support new growth opportunities in nephrology and immunology [5] - The company is actively pursuing business development opportunities, including the acquisition of Hai Bio, to enhance its pipeline [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the foundational position of the company for future capital deployment and growth opportunities [6] - The company is monitoring potential changes in drug pricing policies and tariffs, which could impact negotiations in the EU [14][15] Other Important Information - The company is excited about the potential of its pipeline assets, particularly in rare diseases and kidney diseases, as highlighted in an upcoming investor presentation [40][41] - The company is leveraging AI technology to identify patients for its therapies, indicating a focus on innovative approaches in patient engagement [49] Q&A Session Summary Question: How is the firm balanced now in terms of various disease areas? - The company is leveraging existing expertise in rare diseases while expanding into nephrology and immunology through strategic acquisitions [10] Question: What is the comfort level among PCP providers with the use of blood-based biomarker tests for Alzheimer's? - PCP providers are already using blood-based biomarkers alongside PET scans, indicating a growing acceptance of these tests [26] Question: What are the expectations for the upcoming readouts from the company's trials? - The company anticipates steady progression in growth and is optimistic about the potential for inflection points with new diagnostic tests and treatment methods [27]

Core Viewpoint - The treatment for Amyotrophic Lateral Sclerosis (ALS) has entered a new era of precision intervention targeting pathogenic genes, with the successful administration of tofersen injection for SOD1 gene mutation patients in Guangzhou [1][3]. Group 1: Disease Overview - ALS, commonly known as "Lou Gehrig's disease," leads to progressive death of motor neurons in the brain and spinal cord, resulting in muscle weakness and atrophy, with a typical survival period of 3 to 5 years post-diagnosis [3]. - SOD1 is the most common pathogenic gene among ALS patients in China, with an average onset age of around 50 years, often starting from the lower limbs [3]. Group 2: Treatment Development - Tofersen injection, approved in China in September 2024, works by reducing the synthesis and accumulation of toxic SOD1 protein, thereby slowing down motor neuron damage [3]. - The rapid application of tofersen is attributed to the national rare disease prevention strategy and innovative drug policies, with the Guangzhou region's health insurance including it in their coverage [3]. Group 3: Industry Response - The emergence of breakthrough therapies has sparked hope among patients, as noted by leaders in the rare disease care community [4]. - The development and market introduction of tofersen injection have been positively acknowledged by organizations promoting the translation of scientific research into patient care [4].

Core Insights - Biogen and City Therapeutics have announced a strategic collaboration to develop novel RNA interference (RNAi) therapies, combining Biogen's drug development expertise with City Therapeutics' RNAi engineering technologies [1][2][3] - The collaboration will initially focus on a target related to central nervous system diseases, utilizing advanced drug delivery technologies for systemic administration [2][3] - City Therapeutics will receive $46 million, including a $16 million upfront payment and a $30 million investment, with potential milestone payments of up to $1 billion based on development success [3] Company Overview - Biogen is a leading biotechnology company founded in 1978, focused on innovative science to deliver new medicines and create shareholder value [4] - City Therapeutics is a biopharmaceutical company specializing in next-generation RNAi technologies, aiming to expand the therapeutic reach of RNAi-based medicines [6]

Core Viewpoint - Japan's Eisai and Biogen will relocate part of the production capacity for Lecanemab to the United States [1] Group 1 - The decision to move production capacity indicates a strategic shift towards enhancing operational efficiency and meeting market demand in the U.S. [1]

Group 1 - The article analyzes outside days in the S&P 500 Index and individual stocks, identifying potential trading setups based on these patterns [1][2] - A total of 15,300 outside days were recorded since the beginning of 2024, with stocks showing an average return of 0.80% over the next month after outside days, compared to 0.65% for non-outside days [2][3] - The analysis indicates that stocks closing below the prior day's low after an outside day have the best average return of 0.86%, while those closing above the prior day's high have the lowest average return of 0.73% [3][4] Group 2 - Outside days are considered potential reversal points, with the analysis further broken down by stocks near 52-week highs or lows [6] - Stocks near a 52-week high that experienced a bearish outside day had an average return of 0.89%, with only 44% beating the S&P 500, suggesting a headwind for these stocks [7] - Conversely, stocks near a 52-week low that closed above the prior day's high after a bullish outside day averaged a return of 2.84%, with 67% of returns positive and 56% beating the S&P 500, indicating a strong reversal signal [8][10] Group 3 - The performance of call options on stocks near a 52-week low after bullish outside days yielded an average return of 33% per trade, with one-third of trades doubling [11][12] - Recent signals for potential turnarounds include PepsiCo Inc, Campbell's, and Biogen Inc, suggesting these stocks may be ripe for investment based on the analysis [12]

Core Insights - Jeito Capital has promoted Mehdi Ainouche to Partner and Julien Elric to Senior Principal, reflecting the firm's growth and commitment to internal talent development [1][6] Group 1: Promotions and Roles - Mehdi Ainouche joined Jeito in 2020 and has played a crucial role in the investment cycle, particularly with the successful sale of EyeBio to Merck & Co for up to $3 billion [2][3] - Julien Elric joined Jeito in 2021 and has been instrumental in financing and clinical development strategies, notably contributing to the investment and exit of HI-Bio acquired by Biogen Inc. for up to $1.8 billion [4][5] Group 2: Company Overview - Jeito Capital is a leading global Private Equity fund focused on biopharma, dedicated to financing and accelerating medical innovations with a patient benefit-driven approach [7] - The firm has built a diversified portfolio of clinical biopharmas addressing high unmet medical needs, with a presence in Europe and the United States [7]

Company Overview - Jeito Capital is a leading independent Private Equity fund focused on biopharma, dedicated to financing and accelerating the development of groundbreaking medical innovations [7] - The firm has a diversified portfolio of clinical biopharmas that address high unmet medical needs, with a strong presence in Europe and the United States [7] Promotions and Team Development - Mehdi Ainouche has been promoted to Partner, and Julien Elric to Senior Principal, reflecting Jeito's commitment to talent development and internal career progression [1][6] - Mehdi joined Jeito in 2020 and has played a crucial role in the investment cycle, particularly noted for the successful sale of EyeBio to Merck & Co for up to $3 billion [2] - Julien joined Jeito in 2021 and has been instrumental in financing and clinical development strategies, contributing to the investment and exit of HI-Bio™ acquired by Biogen Inc. for up to $1.8 billion [4] Leadership Insights - Dr. Rafaèle Tordjman, Founder and CEO of Jeito Capital, expressed delight in the promotions, highlighting the significant contributions of Mehdi and Julien to the firm's mission of unlocking the potential of portfolio companies [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 33-0112644 (I.R.S. Employer Id ...

Core Viewpoint - Biogen reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, missing the Zacks Consensus Estimate of $3.32, with an 18% year-over-year decline in earnings due to a $165 million upfront payment to Stoke Therapeutics for a collaboration agreement [1][2][19] Financial Performance - Total revenues for Q1 2025 were $2.43 billion, reflecting a 6% year-over-year increase on a reported basis and an 8% increase on a constant-currency basis, surpassing the Zacks Consensus Estimate of $2.23 billion [2] - Total product sales reached $1.73 billion, up 1% year over year on a reported basis and 3% on a constant-currency basis [4] - Contract manufacturing and royalty revenues surged 61% year over year to $293 million, while Alzheimer's collaboration revenues increased to $33 million from $3 million in the prior year [5][6] Product Sales Breakdown - Multiple sclerosis (MS) revenues totaled $953 million, down 11% on a reported basis due to generic competition for Tecfidera [9] - Sales of Spinraza rose 24.2% to $423.9 million, exceeding the Zacks Consensus Estimate of $365 million [12] - New drug Qalsody for ALS recorded sales of $15.5 million, while Zurzuvae for postpartum depression generated $28 million in sales, reflecting a 21.7% sequential increase [13][14] Cost and Guidance - Adjusted R&D expenses decreased 3% year over year to $427 million, while adjusted SG&A expenses rose 1% to $572 million [16] - The company reaffirmed its total revenue guidance for 2025, expecting a mid-single-digit percentage decline in constant currency terms compared to 2024, and lowered its adjusted EPS guidance to a range of $14.50 to $15.50 [18][19] Market Performance - Year to date, Biogen's shares have declined 20.9%, compared to a 3.3% decrease in the industry [3]